453 related articles for article (PubMed ID: 27114418)
21. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
22. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
23. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
[TBL] [Abstract][Full Text] [Related]
24. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
25. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
Chun HS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee CH; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Lee JH; Kim SU
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):378-385. PubMed ID: 32011388
[TBL] [Abstract][Full Text] [Related]
26. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
Song BG; Sinn DH; Chi S; Kim K; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1447-1452. PubMed ID: 30063482
[TBL] [Abstract][Full Text] [Related]
27. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
28. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
[TBL] [Abstract][Full Text] [Related]
29. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
Chida T; Ohta K; Noritake H; Matsushita M; Murohisa G; Kageyama F; Sasada Y; Oyaizu T; Tsugiki M; Tamakoshi K; Nakajima T; Suda T; Kawata K
Sci Rep; 2024 May; 14(1):10864. PubMed ID: 38740815
[TBL] [Abstract][Full Text] [Related]
30. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis.
Cheung KS; Seto WK; Fung J; Mak LY; Lai CL; Yuen MF
World J Gastroenterol; 2017 Nov; 23(44):7863-7874. PubMed ID: 29209127
[TBL] [Abstract][Full Text] [Related]
31. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
Yu ML; Lin SM; Lee CM; Dai CY; Chang WY; Chen SC; Lee LP; Lin ZY; Hsieh MY; Wang LY; Chuang WL; Liaw YF
Hepatology; 2006 Nov; 44(5):1086-97. PubMed ID: 17058238
[TBL] [Abstract][Full Text] [Related]
32. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals.
Huang CF; Yeh ML; Huang CI; Liang PC; Lin YH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
Hepatol Int; 2018 Nov; 12(6):544-551. PubMed ID: 30426395
[TBL] [Abstract][Full Text] [Related]
33. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
35. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
36. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
[TBL] [Abstract][Full Text] [Related]
37. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma.
Lin CS; Chang CS; Yang SS; Yeh HZ; Lin CW
Intern Med; 2008; 47(7):569-75. PubMed ID: 18379139
[TBL] [Abstract][Full Text] [Related]
38. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
[TBL] [Abstract][Full Text] [Related]
40. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
